NewEdge Advisors’s Collegium Pharmaceutical COLL Stock Holding History

NewEdge Advisors’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$606K	Sell	16,739 -10,290	-38%	-$352K	﹤0.01%	2020
2026 Q1	$894K	Buy	27,029 +14,348	+113%	+$607K	﹤0.01%	1567
2025 Q4	$587K	Sell	12,681 -6,695	-35%	-$280K	﹤0.01%	1857
2025 Q3	$678K	Buy	19,376 +16,329	+536%	+$568K	﹤0.01%	1639
2025 Q2	$90.1K	Buy	3,047 +2,294	+305%	+$65.4K	﹤0.01%	2455
2025 Q1	$22.5K	Buy	+753	New	+$23K	﹤0.01%	2825
2023 Q3	–	Sell	-136	Closed	-$2.92K	–	3499
2023 Q2	$2.92K	Sell	136 -81	-37%	-$1.84K	﹤0.01%	2980
2023 Q1	$5.21K	Sell	217 -1,621	-88%	-$43K	﹤0.01%	2758
2022 Q4	$37.6K	Buy	+1,838	New	+$37.1K	﹤0.01%	1843

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

NewEdge Advisors's COLL Position: Q2 2026 in Review

NewEdge Advisors reduced its Collegium Pharmaceutical (COLL) stake by 38% in Q2 2026, selling an estimated $352K and leaving 16,739 shares worth $606K. The position accounts for ﹤0.01% of the portfolio, ranked #2020.

NewEdge Advisors first reported a position in COLL in Q4 2022 and has held it in 9 quarters since. The position peaked at $894K in Q1 2026. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

NewEdge Advisors held 16,739 shares of Collegium Pharmaceutical worth $606K as of Q2 2026.
NewEdge Advisors sold 10,290 Collegium Pharmaceutical shares in Q2 2026, an estimated $352K.
Collegium Pharmaceutical made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2020 holding.
NewEdge Advisors first reported a position in Collegium Pharmaceutical in Q4 2022 and has held it in 9 quarters since.
NewEdge Advisors's Collegium Pharmaceutical position peaked at $894K in Q1 2026.
279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.